IpIBA seminar series 2022/2023 “IpIBA seminar series 2022/2023 ““Development of novel nanobodies and scFv based molecules to interfere the metastatic process”
Despite numerous advances in cancer research, the lethality of metastatic tumors has practically not been improved in recent years. In breast cancer, the progression of metastatic disease has a poor prognosis, with 5- year survival rates of less than 20%. In a screening of new factors involved in resistance to tumor stress, several molecular components have been identified. Moreover, it has been shown to be essential in intracellular communication through the uptake of extracellular vesicles (EV), a key part of breast cancer metastasis progression. Identifying the molecular agents involved in the uptake of EVs by breast cancer cells allows for in vitro and in vivo screening of inhibitors to identify selective inhibitors that prevent this process and, therefore, may delay or prevent the progression of breast cancer metastasis.
CIBA, main metting room and online via zoom.